NCT07832032Not yet recruiting
Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine
Biological Profiling Subjects With Migraine
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
There are still no reliable biomarkers for migraine; the diagnosis is based on symptomatology, and the pathogenesis remains largely a mystery. However, the past decade has seen a shift from a trial-and-error treatment strategy to a more biologically driven approach using CGRP-targeted drugs (gepants) and monoclonal antibodies (mAbs). This study aims to profile levels of perivascular and hypothalamic neuropeptides, as well as microRNA (miRNA) and neurotrophins, in individuals with migraine. The study builds on a previous pilot investigation (Neuropeptides during migraine attacks, REK 808581).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 11 Sept 2026
- Start date
- 17 Sept 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Nordlandssykehuset HF
- Diseases
- Migraine
- NCT number
- NCT07832032
What you commit to
- Study type: Observational
- Planned participants: 60
- From 17 Sept 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The subject is unable to differentiate migraine from other concomitant headaches
Other illness
- The subject having chronic migraine or other chronic pain conditions
- The subject has severe psychiatric disorders (including depression), substance abuse, severe somatic disorders, and any medical condition that could alter tear and saliva production.
- Eye disorders that cause pain, require medication or affect tear production.
Other
- Pregnancy
- Smoking
- Subjects using tricyclic antidepressant or CGRP antagonists.
- Contraindication for gepants.
Who the study is looking for
- Informed and written consent.
- Men and women, between 18 and 55 years of age.
- Master a Scandinavian language at level sufficient to fully understand the written and verbal study information.
- Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria for episodic migraine at time of inclusion. They must report at least 1 attack per month requiring the use of acute medication.
- Consent to fill out a headache diary for up to 6 months.
Age in the registry: 18 years to 55 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Departement of Neurology, NLSH HF Coordinator of this site? Confirm its status | Bodø | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.